Acute libido shifts within hours, HPG-axis trends over weeks. Two timelines that matter, what trials documented at each stage, and what doesn't happen.
Kisspeptin's timeline is shorter and more variable than most peptides — and there are really two timelines, not one. The first plays out in minutes to hours after a single injection, where Imperial College trial data documents acute LH, FSH, and testosterone elevations and measurable brain-activity shifts. The second plays out over weeks, where community subcutaneous protocols report cumulative HPG-axis trends and subjective libido changes.
Research-context information only. Kisspeptin is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
This guide separates the two. Most "how long does kisspeptin take to work" answers conflate them, which produces unrealistic expectations in either direction. The acute response is well-evidenced; the cumulative protocol response is largely community-reported with less controlled data behind it.
Most peptides act on a single tissue or receptor system. Kisspeptin acts as the upstream gatekeeper of an entire endocrine cascade — kisspeptin neurons drive GnRH release, GnRH drives pituitary LH and FSH secretion, LH and FSH drive testosterone production in men and follicular development in women.
That cascading architecture creates two distinct response windows:
Acute (single-dose) timeline. Each injection produces a measurable LH pulse within minutes. Testosterone follows within roughly an hour. fMRI studies have documented kisspeptin-induced changes in limbic brain activity during a single 75-minute infusion (Comninos et al., 2017).
Cumulative (protocol) timeline. Sustained pulsatile dosing over days to weeks layers in HPG-axis trends — total testosterone shifts, cycle-timing effects in women, subjective libido and mood changes. This timeline is closer to what community users typically describe when they ask "how long until kisspeptin works."
Both are real. They sit on top of each other.
Acute Timeline: What a Single Dose Does
Imperial College's group has published the most-cited acute kisspeptin data in humans, primarily using kisspeptin-54 (the longer endogenous form, ~28-minute half-life) and to a lesser extent kisspeptin-10 (much shorter half-life, under 4 minutes). Community subcutaneous protocols typically use kisspeptin-10.
0-30 Minutes Post-Injection
LH begins rising. In healthy men receiving a 90-minute IV infusion of kisspeptin-54 at 4 pmol/kg/min, plasma LH rose significantly within the early infusion window (Dhillo et al., 2005).
Brain-activity shifts emerge. The 2017 fMRI study found kisspeptin enhanced limbic responses to sexual stimuli — amygdala, cingulate cortex, globus pallidus — during the same infusion window (Comninos et al., 2017).
Subjective shifts are typically not yet perceptible. Brain changes precede subjective awareness of mood or libido shifts in most published data.
30-90 Minutes Post-Injection
LH peaks. In the Dhillo 2005 protocol, LH continued to climb across the 90-minute infusion, with peak responses near the end of administration.
FSH rises. A smaller and slower response than LH, but consistent in the same direction.
Testosterone begins climbing. Following LH's rise, Leydig-cell testosterone output increases — the lag is typically 30-60 minutes behind LH.
Subjective libido changes start to register in the HSDD trial population. The 2023 men's HSDD trial documented behavioral measures of sexual desire and penile tumescence increases of up to 56% versus placebo following kisspeptin administration (Ertl et al., 2023).
2-4 Hours Post-Injection
Total testosterone has risen in the published men's data. Magnitude varies — Dhillo et al. reported significant increases versus saline control, but the absolute change is modest compared to TRT-induced testosterone elevation.
LH starts to decline as kisspeptin-54 is cleared (~28 min half-life means ~5-6 half-lives have passed by the 3-hour mark).
Subjective libido and mood effects are at or near peak in community reports for kisspeptin-10 protocols.
24 Hours Post-Injection
Hormonal trace returns to baseline. A single kisspeptin dose does not produce sustained 24-hour hormonal elevation. The pulsatile architecture means each injection is a discrete event.
Subjective effects fade in most reports. This is why community protocols rely on daily dosing rather than weekly.
Brain-circuit changes from a single dose have not been measured at 24 hours; the published fMRI work documents acute, in-scanner effects only.
Most community users follow a 30-days-on, 30-days-off pulsatile protocol — typically 125 mcg subcutaneous kisspeptin-10 daily, dosed before bed. The cumulative timeline below reflects what community sources describe at each stage. Trial data exists for the acute and IVF use cases above; the cumulative subcutaneous timeline is largely self-reported and less controlled.
Week 1-2: Early Observations
What community sources commonly report:
Mild libido increases. Often described as a return-to-baseline effect rather than a dramatic shift, particularly in users with healthy pre-protocol HPG-axis function.
Sleep-onset shifts. With pre-bed dosing, some users describe a brief warmth or flushing within 30-60 minutes of injection. Whether this affects sleep quality is variable.
No visible change in body composition. Kisspeptin is not a body-recomposition peptide. Users expecting muscle or fat-loss changes in week 1-2 are typically disappointed.
Mood reports are mixed. Some community sources describe a mild mood lift; others report nothing distinguishable.
What trial data supports for this stage:
The Imperial College kisspeptin-54 IVF and HSDD trials demonstrate that pulsatile or single-dose kisspeptin can produce measurable hormonal and behavioral responses. However, no published trial follows healthy community users through a 30-day daily kisspeptin-10 subcutaneous protocol with longitudinal LH/FSH/T tracking.
Week 3-4: HPG-Axis Shifts
What community sources commonly report:
Stronger libido response. Often described as more sustained day-to-day rather than pulsing only post-injection.
Subjective testosterone-trend signals — morning erections, training performance, recovery — though these are non-specific.
Bloodwork changes for users who test. The most commonly reported pattern: modest LH elevation, modest testosterone elevation within natural-physiologic range, FSH less reliably changed. Community-reported magnitudes vary widely.
What the published evidence shows for this stage:
Direct longitudinal data on healthy men's testosterone trajectory across a 4-week subcutaneous kisspeptin-10 protocol does not exist in PubMed. The strongest analogous evidence comes from work in men with congenital hypogonadotropic hypogonadism, where kisspeptin's ability to engage the HPG axis is established as a diagnostic and therapeutic concept (Dhillo et al., 2005).
In women, kisspeptin-54 has restored LH pulsatility in hypothalamic amenorrhea — but acute administration only, with documented tachyphylaxis on chronic exposure (Jayasena et al., 2014 IVF trigger).
Standard protocols are 30 days on. Some community sources extend to 6-8 weeks. The trade-off:
Potential observations during weeks 5-8:
Continued libido and HPG-axis effects in users who tolerate the extended cycle.
Increasing risk of receptor desensitization. Continuous or near-continuous kisspeptin exposure causes KISS1R downregulation and blunted LH response — well-documented in chronic infusion studies (Dhillo et al., 2005).
Diminishing acute response per dose. Users who track LH often see smaller per-injection LH bumps in week 6-8 versus week 1-2.
This is why the standard protocol is 30 on / 30 off rather than continuous. The off-cycle window restores receptor sensitivity.
Post-Cycle: Washout
Days 1-7 after stopping:
Acute hormonal effects fade within hours of the final dose.
HPG-axis returns to its pre-protocol set point. Because kisspeptin works upstream and stimulates rather than suppresses LH/FSH, there is no documented HPG-axis suppression to recover from — unlike exogenous testosterone or AAS cycles.
Subjective libido and mood typically return to baseline within the first week.
Days 7-30 after stopping:
KISS1R receptor sensitivity recovers if any desensitization occurred during the on-cycle.
The receptor reset is the rationale for the 30-day off period before the next cycle.
This recovery profile is fundamentally different from suppressive protocols. Kisspeptin does not require post-cycle therapy in the way that exogenous androgens do.
Biomarker Watch: What to Track
For users tracking response objectively, the relevant biomarkers depend on sex and protocol intent.
Men
LH and FSH. Baseline pre-protocol, then mid-cycle (day 14-21). Expect modest elevation if the protocol is engaging the axis.
Total testosterone. Same timing. Trend matters more than single values; morning draws (7-10 a.m.) for consistency.
Free testosterone or SHBG. SHBG often shifts modestly when total testosterone changes.
Estradiol (sensitive assay). Total testosterone elevation can produce small E2 shifts via aromatization. Worth tracking for users who run extended cycles.
Women (Fertility/Cycle Protocols)
LH surge timing. OPK strips or quantitative serum LH around the expected ovulation window. Kisspeptin-54 IVF protocols time oocyte retrieval ~36 hours after the kisspeptin trigger (Abbara et al., 2015).
FSH. Day 3 cycle baseline, before and after a kisspeptin cycle.
Estradiol and progesterone. Standard cycle-tracking biomarkers.
Both Sexes
Resting heart rate and blood pressure. Acute kisspeptin can produce mild flushing; whether this translates to measurable BP changes in subcutaneous protocols is not well-documented but worth tracking.
Subjective libido scoring (validated tools like FSFI for women or IIEF for men) at baseline and end-of-cycle.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
30ml from $18.75 · Ships fast · Code thepeptidecatalog
Variability Factors: Why Responses Differ
Kisspeptin response variability is larger than most peptides because it depends on the state of the HPG axis at baseline, not just the peptide itself.
HPG-Axis Status
Healthy axis with normal LH/FSH/T: Less room for kisspeptin-driven elevation. Response is real but smaller in absolute terms.
Functional hypogonadism (low T with low-normal LH/FSH): Larger documented response. Kisspeptin's ability to engage the axis is the diagnostic basis for distinguishing central from gonadal hypogonadism.
Primary hypogonadism (testicular failure): Minimal testosterone response despite LH elevation. The signal can't reach failed Leydig cells.
Suppressed axis from prior AAS use: Variable. Kisspeptin can stimulate LH/FSH, but full recovery depends on factors beyond kisspeptin.
Age
Older men show preserved hypothalamic kisspeptin response in trial data. The Imperial College group documented preserved hypothalamic responses to kisspeptin-54 in healthy older men. Whether the downstream testosterone response is equivalent depends on age-related testicular changes.
Sex
Men: Most published acute trial data and most community reports.
Women: Cycle-phase dependent. Late follicular and ovulatory windows show different LH responses than the luteal phase. IVF trigger protocols time kisspeptin to specific cycle points for this reason.
Stack
Kisspeptin + PT-141: Different mechanisms (HPG axis vs. melanocortin MC4R). No published combination trials. Community use exists but evidence is anecdotal. See kisspeptin vs PT-141.
Kisspeptin + GnRH analogs: Should not be combined without clinical supervision; redundant axis stimulation.
Route
Subcutaneous (community standard): Bioavailability is reasonable for both kisspeptin-10 and kisspeptin-54.
Intranasal: Studied for kisspeptin in healthy men; absorption is lower than IV but reproductive hormone responses are documented. Less common in community protocols.
IV (research only): Highest bioavailability; not practical outside trials.
Product Quality
Research-peptide quality varies. Kisspeptin's small dose window and pulsatile pharmacology mean degraded or low-purity product can produce no measurable response. Third-party COA verification matters.
Managing expectations is part of the timeline. The kisspeptin literature is unusually strong for a community peptide — but it does not support the more aggressive claims sometimes made in marketing.
Kisspeptin is not testosterone replacement. Trial-documented testosterone elevations are within physiologic range, smaller than TRT-induced increases, and depend on a functioning HPG axis downstream. Users with severely suppressed or primary-failure axes will not see TRT-equivalent results.
Kisspeptin does not produce dramatic body composition changes. No published data shows muscle gain, fat loss, or recomposition outcomes from kisspeptin protocols. Indirect effects through testosterone elevation are theoretical and small.
Acute libido response is well-evidenced; durable HPG-axis recovery effects are less so. The acute LH/FSH/T pulse and the brain-circuit fMRI findings are robust. Sustained HPG-axis "recovery" or "reset" claims from 30-day protocols rest mostly on community reports without controlled longitudinal data.
Kisspeptin will not override receptor desensitization. Continuous exposure suppresses rather than stimulates LH. Users dosing more frequently than pulsatile protocols recommend often see diminishing returns rather than amplified effects.
Female users will not see linear week-by-week changes. The female cycle creates non-linear hormonal context. Effects depend on cycle phase, baseline cycle regularity, and protocol timing relative to the follicular/ovulatory/luteal windows.
Kisspeptin does not "cure" HSDD or hypogonadism. Trial data documents measurable improvements; it does not document permanent remission. Off-cycle, baseline status returns.
When to Reassess the Protocol
Signs the Protocol Is Engaging the Axis
Mid-cycle bloodwork showing LH/FSH/T elevation versus baseline.
Subjective libido increase that is consistent rather than only post-injection.
For women on cycle-support protocols: documented LH-surge timing matching protocol intent.
Signs to Reassess
No measurable change after 2-3 weeks of consistent dosing. Verify product quality (COA), reconstitution, injection technique, and dose. Confirm pulsatile timing rather than continuous exposure.
Diminishing response across the cycle. Suggests receptor desensitization. Shorter cycles or longer off-periods may help.
Adverse effects: persistent flushing, headache, injection-site reactions — see the kisspeptin dosing guide for typical side-effect profile.
Bloodwork shifts inconsistent with protocol intent — for example, FSH elevation without testosterone change in a male protocol designed for testosterone support. Discuss with a clinician familiar with HPG-axis pharmacology.
When to Stop
Goal achieved: Subjective and biomarker targets met; consider the standard 30-day off-cycle.
No response after 4 weeks: The HPG axis may not be the limiting factor for the user's goal. Direct receptor agonists (PT-141) or other approaches may be more appropriate.
Hormonally-sensitive conditions: Discontinue and seek clinical guidance. Kisspeptin stimulates sex steroid production and is contraindicated in hormone-sensitive cancers.
Frequently Asked Questions
How long does kisspeptin take to work?
Two different timelines. Acute LH/FSH/testosterone elevation has been measured within 30-90 minutes of injection in clinical studies. Cumulative effects on libido and HPG-axis trends are typically reported by community sources over 2-4 weeks.
Why are there two kisspeptin timelines?
Kisspeptin acts upstream of GnRH, so each injection produces a measurable acute hormone pulse within hours. Sustained protocols (daily dosing for weeks) layer cumulative LH/FSH/testosterone trends and brain-circuit changes on top of that acute response.
When do most users notice libido changes on kisspeptin?
Imperial College HSDD trial data documented behavioral and brain-activity changes after a single kisspeptin-54 infusion. Community subcutaneous protocols typically report subjective libido shifts within the first 1-2 weeks of daily dosing.
Does kisspeptin raise testosterone like TRT?
No. Kisspeptin stimulates the HPG axis upstream — LH and FSH rise, then testosterone follows. This is different from exogenous TRT, which suppresses LH/FSH. Trial-documented testosterone increases from kisspeptin are smaller and more variable than TRT.
How long do kisspeptin effects last after stopping?
Acute effects from a single injection clear within hours given kisspeptin-54's ~28-minute half-life. Cumulative HPG-axis changes from a 30-day protocol typically wash out within 1-2 weeks based on natural feedback dynamics.
What if I see no change after 2 weeks of kisspeptin?
Several possibilities: HPG-axis status (if axis is already healthy, room for further stimulation is limited), receptor desensitization from too-frequent dosing, or product-quality issues. Pulsatile dosing matters — continuous exposure suppresses rather than stimulates LH.
Can women track kisspeptin results during a cycle?
Trial data from kisspeptin-54 IVF protocols show timed LH-surge induction within roughly 12-24 hours of injection. For non-IVF community use, cycle-tracking tools and OPK strips can capture the timing of LH rises in protocols designed around ovulation support.
Research Supplies for Kisspeptin
Hand-picked storage, injection, and recovery supplies paired with Kisspeptin protocols.
Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609-6615. PMID: 16174713
Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709-719. PMID: 28112678
Ertl N, Mills EG, Wall MB, et al. Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(2):e2254313. PMID: 36735255
Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-3677. PMID: 25036713
Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. J Clin Endocrinol Metab. 2015;100(9):3322-3331. PMID: 26192876
Jayasena CN, Nijher GM, Chaudhri OB, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315-4323. PMID: 19820030
For educational and research purposes only. This is not medical advice. Kisspeptin is not FDA-approved for any indication.
